BD CY Q4 ’18 (FY Q1 ’19) Earnings Update
BD held their Q4 ’18 earnings call and provided a brief update on their diabetes business unit. Senior management disclosed they have filed their T2DM patch pump in the US and European and anticipate a launch in late 2019. When asked by an analyst about their market approach for the T2DM patch pump, senior management commented that BD is in the process of defining their channel strategy. Furthermore, management does not anticipate any new clinical data to presented at ADA 2019.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.